Vaxart (OTCQX: VXRT) announced that its management team will participate in the BTIG Biotechnology Conference 2026, held virtually on Tuesday, July 28, 2026, in a 1x1 meetings format.
The company develops oral recombinant pill vaccines targeting coronavirus, norovirus, influenza and a therapeutic HPV vaccine, using a proprietary non‑refrigerated delivery platform and has filed broad domestic and international patent applications.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – VXRT
+0.64%
+0.64%Session close to close
In the Jul 21 session, VXRT gained 0.64%, reflecting a mild positive market reaction.
The historical record includes news_id 1078279 with a -10.81% 24-hour price reaction, while this ann...
Analysis
The historical record includes news_id 1078279 with a -10.81% 24-hour price reaction, while this announcement only schedules investor meetings. The active S-3 shelf adds financing context; subsequent disclosures should clarify operational progress.
Highlighted board continuity and oversight of Phase 2b COVID-19 work
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive or informational announcements produced mixed outcomes, with two positive events aligned and two positive or informational events diverging from the subsequent price reaction.
"developing a range of oral recombinant vaccines based on its proprietary delivery platform"
Vaccines made using recombinant technology are created by inserting genetic instructions for a specific part of a pathogen (like a protein) into harmless cells or microbes, which then produce that piece for use as the vaccine ingredient. For investors, they matter because this approach can speed development, allow precise targeting and scalable manufacturing—similar to ordering a single, repeatable part from a factory instead of growing whole organisms—affecting costs, timelines and supply reliability.
adenovirusmedical
"oral vaccination using adenovirus and TLR3 agonists"
Adenovirus is a family of viruses that commonly cause mild respiratory or eye infections and is also used in medicine as a delivery vehicle to carry genes or vaccine material into cells. Investors monitor developments involving adenoviruses because safety signals, clinical trial results, or regulatory decisions tied to therapies and vaccines that use them can quickly change a company's perceived risks and potential market value—like whether a delivery truck arrives intact determines whether goods reach buyers.
tlr3 agonistsmedical
"oral vaccination using adenovirus and TLR3 agonists"
TLR3 agonists are drugs or molecules that activate Toll-like receptor 3, an immune system sensor that detects double-stranded RNA and triggers an antiviral and inflammatory response. Think of TLR3 as a smoke detector and an agonist as the signal that sets off the alarm; activating this pathway can boost vaccine responses, stimulate cancer-fighting immune cells, or enhance antiviral defenses. They matter to investors because successful TLR3 agonists can become components of vaccines, cancer immunotherapies, or antiviral treatments, influencing clinical trial value, regulatory review, manufacturing needs, and market opportunity.
immune-oncologymedical
"Vaxart’s first immune-oncology indication"
Immune-oncology is a branch of medicine that develops treatments which help a patient’s own immune system find and fight cancer, rather than attacking tumors directly with chemicals or radiation. For investors, it matters because these therapies can create large new markets or transform care pathways when successful, but they also carry high clinical trial, regulatory and commercialization risk—think of them as high-reward, high-uncertainty innovations like breakthrough technologies in other industries.
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026.
Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.
About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact Vaxart Media and Investor Relations: FINN Partners IR@vaxart.com
FAQ
When will Vaxart (VXRT) participate in the BTIG Biotechnology Conference 2026?
Vaxart will participate in the BTIG Biotechnology Conference 2026 on Tuesday, July 28, 2026. According to Vaxart, the event will be held virtually and will feature 1x1 meetings between the company’s management team and interested institutional investors.
Is the BTIG Biotechnology Conference 2026 with Vaxart (VXRT) a virtual event?
Yes, the BTIG Biotechnology Conference 2026 featuring Vaxart is a fully virtual event. According to Vaxart, its management will take part in 1x1 meetings with institutional investors conducted online rather than at a physical conference location.
How can institutional investors schedule a 1x1 meeting with Vaxart (VXRT) at the BTIG conference?
Institutional investors can request 1x1 meetings with Vaxart’s management by contacting their BTIG representative. According to Vaxart, all conference meetings are arranged directly through BTIG, which coordinates schedules and virtual access for interested professional investors.
What type of vaccines is Vaxart (VXRT) developing as of July 2026?
Vaxart is developing a range of oral recombinant pill vaccines using its proprietary delivery platform. According to Vaxart, current programs target coronavirus, norovirus, influenza, and a therapeutic human papillomavirus (HPV) vaccine, its first immune-oncology indication, with broad patent applications filed.
What is unique about Vaxart’s (VXRT) oral vaccine delivery platform?
Vaxart’s platform delivers vaccines as pills that do not require refrigeration and avoid needle-stick risks. According to Vaxart, this recombinant pill approach may enable oral versions of existing vaccines and support new vaccine indications using adenovirus and TLR3 agonist technologies.
How can investors or media contact Vaxart (VXRT) regarding its BTIG conference participation?
Investors and media can contact Vaxart through FINN Partners via IR@vaxart.com. According to Vaxart, this contact is for media and investor relations inquiries related to its programs, including participation in events like the BTIG Biotechnology Conference 2026.
